Authors: Rocío García-Marín, Virginia N. Cabal, Carmen Fernández-Cedrón Bermejo, Cristina Riobello, Laura Suárez-Fernández, Helena Codina-Martínez, Ainhoa Navarro-García, Sara Lucila Lorenzo-Guerra, Jorge García-Martínez, Blanca Vivanco, Fernando López, José Luis Llorente, and Mario A. Hermsen
American Academy of Otolaryngology-Head and Neck Surgery Foundation, March 29, 2022
The authors of this study aimed to characterize CAE606 cells derived from a squamous cell carcinoma (SCC) of the external auditory canal (EAC) and to demonstrate the suitability of this cell model for testing candidate therapeutic agents. The Axion BioSystems Omni was used to evaluate CAE606 cell migration in a standard wound-healing assay following treatment with cell cycle inhibitor, palbociclib. All in all, this study demonstrates the value of CAE606 cell line in investigating new therapeutics targeting cell cycle control pathways.
